Vanessa S Virgini1, Nicolas Rodondi1, Peggy M Cawthon1, Stephanie Litwack Harrison1, Andrew R Hoffman1, Eric S Orwoll1, Kristine E Ensrud1, Douglas C Bauer1. 1. Department of Internal Medicine (V.S.V.), University Hospital of Zürich, 8091 Zürich, Switzerland; Department of General Internal Medicine (N.R.), Inselspital, University Hospital of Bern, 3010 Bern, Switzerland; California Pacific Medical Center Research Institute (L.H.), San Francisco, California 94107; Stanford University Medical School (A.R.H.), Palo Alto, California 94305; Bone and Mineral Unit (E.S.O.), Oregon Health & Science University, Portland, Oregon 97239; Department of Medicine (K.E.E.) and Division of Epidemiology and Community Health (K.E.E.), University of Minnesota, Minneapolis, Minnesota 55455; Center for Chronic Disease Outcomes Research (K.E.E.), Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota 55417; and Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California 94143.
Abstract
CONTEXT: Both subclinical thyroid dysfunction and frailty are common among older individuals, but data on the relationship between these 2 conditions are conflicting. OBJECTIVE: The purpose of this study was to assess the cross-sectional and prospective associations between subclinical thyroid dysfunction and frailty and the 5 frailty subdomains (sarcopenia, weakness, slowness, exhaustion, and low activity). SETTING AND DESIGN: The Osteoporotic Fractures in Men Study is a prospective cohort study. PARTICIPANTS: Men older than 65 years (n = 1455) were classified into 3 groups of thyroid status: subclinical hyperthyroidism (n = 26, 1.8%), subclinical hypothyroidism (n = 102, 7.0%), and euthyroidism (n = 1327, 91.2%). MAIN OUTCOME MEASURES: Frailty was defined using a slightly modified Cardiovascular Health Study Index: men with 3 or more criteria were considered frail, men with 1 to 2 criteria were considered intermediately frail, and men with no criteria were considered robust. We assessed the cross-sectional relationship between baseline thyroid function and the 3 categories of frailty status (robust/intermediate/frail) as well as the prospective association between baseline thyroid function and subsequent frailty status and mortality after a 5-year follow-up. RESULTS: At baseline, compared with euthyroid participants, men with subclinical hyperthyroidism had an increased likelihood of greater frailty status (adjusted odds ratio, 2.48; 95% confidence interval, 1.15-5.34), particularly among men aged <74 years at baseline (odds ratio for frailty, 3.63; 95% confidence interval, 1.21-10.88). After 5 years of follow-up, baseline subclinical hypothyroidism and hyperthyroidism were not consistently associated with overall frailty status or frailty components. CONCLUSION: Among community-dwelling older men, subclinical hyperthyroidism, but not subclinical hypothyroidism, is associated with increased odds of prevalent but not incident frailty.
CONTEXT: Both subclinical thyroid dysfunction and frailty are common among older individuals, but data on the relationship between these 2 conditions are conflicting. OBJECTIVE: The purpose of this study was to assess the cross-sectional and prospective associations between subclinical thyroid dysfunction and frailty and the 5 frailty subdomains (sarcopenia, weakness, slowness, exhaustion, and low activity). SETTING AND DESIGN: The Osteoporotic Fractures in Men Study is a prospective cohort study. PARTICIPANTS: Men older than 65 years (n = 1455) were classified into 3 groups of thyroid status: subclinical hyperthyroidism (n = 26, 1.8%), subclinical hypothyroidism (n = 102, 7.0%), and euthyroidism (n = 1327, 91.2%). MAIN OUTCOME MEASURES: Frailty was defined using a slightly modified Cardiovascular Health Study Index: men with 3 or more criteria were considered frail, men with 1 to 2 criteria were considered intermediately frail, and men with no criteria were considered robust. We assessed the cross-sectional relationship between baseline thyroid function and the 3 categories of frailty status (robust/intermediate/frail) as well as the prospective association between baseline thyroid function and subsequent frailty status and mortality after a 5-year follow-up. RESULTS: At baseline, compared with euthyroid participants, men with subclinical hyperthyroidism had an increased likelihood of greater frailty status (adjusted odds ratio, 2.48; 95% confidence interval, 1.15-5.34), particularly among men aged <74 years at baseline (odds ratio for frailty, 3.63; 95% confidence interval, 1.21-10.88). After 5 years of follow-up, baseline subclinical hypothyroidism and hyperthyroidism were not consistently associated with overall frailty status or frailty components. CONCLUSION: Among community-dwelling older men, subclinical hyperthyroidism, but not subclinical hypothyroidism, is associated with increased odds of prevalent but not incident frailty.
Authors: Bu B Yeap; Helman Alfonso; Stephen A Paul Chubb; John P Walsh; Graeme J Hankey; Osvaldo P Almeida; Leon Flicker Journal: Clin Endocrinol (Oxf) Date: 2012-05 Impact factor: 3.478
Authors: Graziano Ceresini; Fulvio Lauretani; Marcello Maggio; Gian Paolo Ceda; Simonetta Morganti; Elisa Usberti; Carlo Chezzi; Rita Valcavi; Stefania Bandinelli; Jack M Guralnik; Anne R Cappola; Giorgio Valenti; Luigi Ferrucci Journal: J Am Geriatr Soc Date: 2008-11-19 Impact factor: 5.562
Authors: Annewieke W van den Beld; Theo J Visser; Richard A Feelders; Diederick E Grobbee; Steven W J Lamberts Journal: J Clin Endocrinol Metab Date: 2005-09-20 Impact factor: 5.958
Authors: Avantika C Waring; Nicolas Rodondi; Stephanie Harrison; Alka M Kanaya; Eleanor M Simonsick; Iva Miljkovic; Suzanne Satterfield; Anne B Newman; Douglas C Bauer Journal: Clin Endocrinol (Oxf) Date: 2012-06 Impact factor: 3.478
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Danka J F Stuijver; Bregje van Zaane; Erica Romualdi; Dees P M Brandjes; Victor E A Gerdes; Alessandro Squizzato Journal: Thromb Haemost Date: 2012-09-26 Impact factor: 5.249
Authors: George C Wang; Monica V Talor; Noel R Rose; Anne R Cappola; Roger B Chiou; Carlos Weiss; Jeremy D Walston; Linda P Fried; Patrizio Caturegli Journal: J Clin Endocrinol Metab Date: 2010-01-08 Impact factor: 5.958
Authors: Annewieke W van den Beld; Jean-Marc Kaufman; M Carola Zillikens; Steven W J Lamberts; Josephine M Egan; Aart J van der Lely Journal: Lancet Diabetes Endocrinol Date: 2018-07-17 Impact factor: 32.069
Authors: D Segna; D C Bauer; M Feller; C Schneider; H A Fink; C E Aubert; T-H Collet; B R da Costa; K Fischer; R P Peeters; A R Cappola; M R Blum; H A van Dorland; J Robbins; K Naylor; R Eastell; A G Uitterlinden; F Rivadeneira Ramirez; A Gogakos; J Gussekloo; G R Williams; A Schwartz; J A Cauley; D A Aujesky; H A Bischoff-Ferrari; N Rodondi Journal: J Intern Med Date: 2017-10-16 Impact factor: 8.989
Authors: M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti Journal: J Endocrinol Invest Date: 2020-07-21 Impact factor: 4.256